Tulane Educational Fund is a private company headquartered in the United States specializing in radio broadcasting stations.

Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC.

Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788.

Part of Gilead Sciences, Inc., IBC Pharmaceuticals, Inc. is a company headquartered in Morris Plains, NJ, that produces biological products.

Develops products for the treatment of human immune systems disorders and diseases

Panacos Pharmaceuticals, Inc., a development stage biotechnology company, engages in the discovery and development of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other human viral diseases. The company’s discovery technologies focus on novel targets in the virus life cycle, including virus maturation and virus fusion. Its product pipeline includes second- and third-generation programs in HIV maturation inhibition. The company was founded in 1999 and is headquartered in Watertown, Massachusetts.

Originating as ConjuChem Biotechnologies Inc. of Montreal, Quebec, Canada - ConjuChem, LLC, is now a privately held Los Angeles, CA-based biotechnology company, dedicated to the discovery of novel therapeutics with an initial focus on diabetes. ConjuChem is currently managing several research programs in-house and has one product in clinical development. They are focused on discovering and developing new drugs based on their novel technology platforms called Drug Affinity Complex (DAC™) and Preformed Conjugate-Drug Affinity Complex (PC-DAC™). When applied to a compound, DAC™ or PC-DAC™ can create a new drug with similar therapeutic activity but a significantly longer duration of activity in the body. One of the greatest opportunities for the DAC™ and PC-DAC™ technology from ConjuChem is its potential to enhance the therapeutic activity of peptides by increasing the half-life and efficacy, while improving tolerability. Specifically, peptides generally have short durations of vivo activity, which significantly limits their potential as commercially viable therapeutic products. The DAC™ and PC-DAC™ technology platforms have broad applicability in several targeted indications. They believe there are many attractive potential targets for the constructs being built from these technology platforms. ConjuChem routinely evaluates partnership agreements with other biopharmaceutical firms for research collaborations and licensing agreements while also assessing which programs They may consider developing and commercializing on its own.

Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products. The company operates in two segments, Pharmaceuticals, and Nutritionals. The Nutritionals segment is operated through the company's subsidiary Mead Johnson Nutrition Company (Mead Johnson). The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business.

Founded in 2013, Frontier Biotechnologies is a commercial-stage biopharmaceutical company headquartered in China with global vision and world-class competitiveness. Frontier Biotech is committed to discovering, development, manufacturing, and commercialization of innovative medicines that improve patient health. Their medicines typically address the unmet medical needs of patients in the areas of anti-HIV treatment and pain management. Frontier Biotech's first commercial product was approved by the National Medical Product Administration (NMPA), which is the counterpart of the Food and Drug Administration (FDA) in China, in May 2018 through a priority review process and has gained accelerated approval. Two additional drug candidates are currently undergoing multiple clinical trials in Phase I and Phase II in both China and the United States. Frontier Biotech brings together many of the best scholars, scientists, and professionals in R&D, senior management, marketing, international business development, and manufacturing. At Frontier Biotech, their long-standing commitment to excellence is in everything they do throughthe entire development cycle from drug discovery, preclinical research to global clinical development. This approach has enabled Frontier Biotech to emerge in the global market as a competitive player in the field of HIV long-acting treatment and immunotherapy.

ConjuChem Biotechnologies, Inc. develops peptide based pharmaceuticals. Its peptide products are used to treat diseases such as congestive heart failure, diabetes, HIV/AIDS and human growth deficiencies. ConjuChem Biotechnologies is a research and development company that develops technology that binds peptides to albumin in order to extend the half life of drugs from minutes to days. The company was founded on August 25, 2009 and is headquartered in Montréal, Canada.

Tianjin Fusu Biotechnology Co., Ltd., established on 2002-02-08, Business scope includes biomedical technology research and development,to develop;Chemical and pharmaceutical technology research and development,to develop;technical consulting,Technical Services,technology transfer;international trade;Import and export of goods and technology(law,Except where prohibited by law)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Immunomedics is a biopharmaceutical company that specializes in developing monoclonal antibody-based products for the treatment of cancer and other serious diseases. Its corporate objective is to become a fully-integrated biopharmaceutical company. The company was founded in 1982 and headquartered in Morris Plains, New Jersey.

Sequoia Pharmaceuticals discovers and develops unique treatments for viral diseases including HIV/AIDS and HCV-induced hepatitis with a focus on the growing global problem of drug-resistant disease.\nMost new anti-viral drugs were designed to block the most prevalent form of a pathogen, but these drugs become less potent due to the emergence of drug-resistant mutations. Sequoia's is to discover and develop new antiviral which are active against the most prevalent form of the virus but also anticipates the emergence of drug resistance forms thereby maintaining potency over time.\nSequoia's differentiating approach is to identify a constellation of atomic interaction points which are necessary and sufficient for enzymatic function. Sequoia's protease inhibitors have been designed to interact preferentially with only these atoms, thus allowing non-critical mutations to occur without resulting in a decrease in drug potency.\nThe foundation of Sequoia's novel Resistant-Repellent™ technology is a drug discovery tool that enhances the efficiency with which drugs are designed. It is based on an understanding of the chemical and physical nature of the molecular targets, the enzymes and receptors to which drugs bind, combined with an understanding of the molecular mechanisms that cause drug resistance.\nSequoia is also discovering and developing a unique series of pharmacokinetic enhancers (PKEs) to work in combination with its own, and its partners', antiviral therapies. These sets of molecules improve the PK of existing therapeutics and reduce interpatient variability. This represents a unique approach to an important need in HIV treatment today. Sequoia is also looking to extend this novel PKE approach to other areas.\nIts PKEs are designed to inhibit a particular CYP isozyme and therefore change the metabolism of a co-administered therapeutic agent. The combination of PK Enhancer and the therapeutic agent enables reduced dosage and less frequent administration of the therapeutic agent.

Chengdu Aoda Biotechnology Co., Ltd., established on 2017-03-13, Business scope includes biotechnology,Medical Technology Development,technical consulting(Does not include health care activities),technology transfer;Import and export of goods and technology;Sales of pharmaceutical intermediates(Does not contain drugs).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

Chiron Corporation (/ˈkaɪrɒn/ KY-ron) was an American multinational biotechnology firm based in Emeryville, California that was acquired by Novartis on April 20, 2006. It had offices and facilities in eighteen countries on five continents. Chiron's business and research was in three main areas: biopharmaceuticals, vaccines, and blood testing. Chiron's vaccines and blood testing units were combined to form Novartis Vaccines and Diagnostics, while Chiron BioPharmaceuticals was integrated into Novartis Pharmaceuticals. In 2014, Novartis completed the sale of its blood transfusion diagnostics unit to Grifols and announced agreements for the sale of its vaccines unit to GlaxoSmithKline.

Part of Biosynth Holding AG, Pepscan Systems BV is a Dutch company that designs, manufactures and uses large combinatorial arrays of peptides, peptidometics and derivatives.

Progenics Pharmaceuticals, Inc., of Tarrytown, N.Y., is a biopharmaceutical company focused on innovative therapeutics for patients suffering from cancer and related conditions. Progenics' pipeline candidates include PSMA ADC, a human monoclonal antibody-drug conjugate in phase 2 testing for treatment of prostate cancer, and preclinical stage novel multiplex phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer. Progenics has exclusively licensed development and commercialization rights for its first commercial product, RELISTOR®, to Salix Pharmaceuticals, Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd. holds an exclusive license for the subcutaneous formulation. RELISTOR (methylnaltrexone bromide) Subcutaneous Injection is a first-in-class treatment for opioid-induced constipation approved in more than 50 countries for patients with advanced illness.